Search clinical trials for: gemtuzumab

Total 736 results

Nantes University Hospital
Chugai Pharmaceutical; French Innovative Leukemia Organisation

Completed

Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (LAM2006IR)

Acute Myeloid Leukemia

France
PETHEMA Foundation

Completed

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Acute Myeloblastic Leukemia

Spain
University Hospital Carl Gustav Carus

Unknown

Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Allogeneic Transplantation

Germany
Pfizer

Completed

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Leukemia, Myeloid, Acute

United States
Pfizer

Completed

CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

Leukemia

United States
University Hospital Heidelberg

Terminated

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG)

Acute Myeloid Leukemia

Germany
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (AML-19)

Leukemia

Belgium, Italy, Netherlands
Versailles Hospital

Unknown

Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg® (MYLOR)

Leukemia, Myeloid, Acute

France
University of Aarhus

Completed

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Denmark
Pfizer

Completed

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

Leukemia

United States
Pfizer

Completed

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Pharmacokinetics | Safety | ECG

Canada, Spain, United States, Hungary, Poland, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Acute Myelogenous Leukemia

United States
Kanisa Pharmaceuticals

Completed

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Leukemia, Myeloid
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
Merck Sharp & Dohme LLC

Terminated

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Leukemia, Myeloid, Acute | Lymphoblastic Leukemia, Acute
Medical College of Wisconsin

Completed

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML

United States
Genta Incorporated

Completed

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
Acute Leukemia French Association

Completed

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML (MYLOFRANCE2)

Acute Myeloid Leukemia

France
Gilead Sciences

Terminated

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (RAINIER)

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Israel, Australia, Italy, Canada, United Kingdom, Switzerland, Germany, Poland, Czechia, Belgium, France
Weill Medical College of Cornell University
Pfizer; Jazz Pharmaceuticals

Terminated

CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO)

Acute Myeloid Leukemia

United States
University Hospital Heidelberg
National Center for Tumor Diseases, Heidelberg

Completed

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM)

Acute Myeloid Leukemia

Germany
Shaare Zedek Medical Center

Recruiting

Vyxeos for Induction of Low- or Intermediate-risk.

Leukemia, Myeloid, Acute

Israel
University of Ulm

Completed

Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Acute Myeloid Leukemia

Germany, Austria
Shanghai Henlius Biotech

Completed

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
Vor Biopharma

Recruiting

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Canada
Boehringer Ingelheim

Completed

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
John Quigley
Pfizer; AbbVie

Active, not recruiting

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Acute Myeloid Leukemia

United States
New York Medical College

Completed

SCT Plus Immune Therapy in Average Risk AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
The Cleveland Clinic
National Cancer Institute (NCI); University of Michigan

Completed

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Zydus Lifesciences Limited

Not yet recruiting

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Metastatic Breast Cancer
German CLL Study Group

Completed

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
Shengjing Hospital

Not yet recruiting

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Breast Cancer

China
Versailles Hospital

Completed

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 (ALFA1401)

Acute Myeloid Leukemia

France
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Brown University
Pfizer; The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
New York Medical College

Completed

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Terminated

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Acute Myeloid Leukemia

Italy
M.D. Anderson Cancer Center

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Genzyme, a Sanofi Company

Terminated

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Australia, United Kingdom, Canada, France
Karolinska University Hospital
Schering Nordiska AB

Completed

Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

B-CLL

Sweden
Latin American Cooperative Onco-Haematology Group...

Unknown

Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome

Peru
Case Comprehensive Cancer Center
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Completed

Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

Leukemia

United States
Gilead Sciences

Terminated

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) (ATLAS)

Idiopathic Pulmonary Fibrosis

United States
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
Genzyme, a Sanofi Company

Completed

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

B Cell Chronic Lymphocytic Leukemia

United States
German CLL Study Group

Completed

Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Leukemia

Germany, Austria
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States

3

Subscribe